Skip to content

Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US

The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN).

Read More

Leave a Reply

Generated by Feedzy
%d bloggers like this: